PTHS

Pelthos Therapeutics Inc

Jun 18 • 04:00PM ET

29.00

+1.99 7.37 %

Healthcare • Biotechnology • USA • Micro • AMEX

Peers: ANIX ATYR COYA CYPH INO LONA NRXS CGTX NRXP KALA

Index	-	P/E	-	EPS (ttm)	-20.65	Insider Own	16.37%	Shs Outstand	3.37M	Perf Week	0.97%
Market Cap	100.80M	Forward P/E	-	EPS next Y	-1.67	Insider Trans	5.85%	Shs Float	2.91M	Perf Month	7.41%
Enterprise Value	121.50M	PEG	-	EPS next Q	-2.82	Inst Own	35.34%	Short Float	1.31%	Perf Quarter	26.27%
Income	-51.59M	P/S	3.64	EPS this Y	55.07%	Inst Trans	4.13%	Short Ratio	2.20	Perf Half Y	32.84%
Sales	27.70M	P/B	2.78	EPS next Y	83.89%	ROA	-70.53%	Short Interest	0.04M	Perf YTD	-6.45%
Book/sh	10.42	P/C	3.13	EPS next 5Y	-	ROE	-333.84%	52W High	54.29 -46.58%	Perf Year	141.67%
Cash/sh	9.27	P/FCF	-	EPS past 3/5Y	-75.48% -82.26%	ROIC	-59.03%	52W Low	11.20 158.93%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- 142.58%	Gross Margin	65.90%	Volatility	5.39% 4.04%	Perf 5Y	-
Dividend TTM	-	EV/Sales	4.39	EPS Y/Y TTM	-11.85%	Oper. Margin	-157.70%	ATR (14)	1.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.83	Sales Y/Y TTM	-	Profit Margin	-186.23%	RSI (14)	61.18	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.76	EPS Q/Q	3.72%	SMA20	8.00%	Beta	3.12	Target Price	57.71
Payout	-	Debt/Eq	1.51	Sales Q/Q	-	SMA50	13.48%	Rel Volume	2.66	Prev Close	27.01
Employees	92	LT Debt/Eq	1.49	Earnings	May 14 BMO	SMA200	9.03%	Avg Volume	17.36K	Price	29.00
IPO	Feb 16, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	10.43% 4.49%	Trades		Volume	46,193	Change	7.37%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-01-26	Initiated	Cantor Fitzgerald	Overweight	$50
Feb-27-26	Initiated	Piper Sandler	Overweight	$48
Dec-03-25	Initiated	Lake Street	Buy	$50
Dec-03-25	Initiated	H.C. Wainwright	Buy	$60
Nov-25-25	Initiated	Roth Capital	Buy	$57
Sep-02-25	Initiated	Oppenheimer	Outperform	$50

May-28-26 05:00PM	Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-26 08:30AM	Pelthos Therapeutics Inc. Q1 2026 Earnings Call Summary (Moby)
May-14-26 07:01PM	Pelthos Therapeutics Inc (PTHS) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com) +6.46%
07:00AM	Pelthos Therapeutics Announces First Quarter 2026 Financial Results (GlobeNewswire)
May-01-26 08:30AM	Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026 (GlobeNewswire)
08:30AM	Loading…
Apr-14-26 08:30AM	Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium (GlobeNewswire)
Apr-10-26 05:00PM	Pelthos Therapeutics Announces CFO Transition (GlobeNewswire)
Mar-31-26 08:30AM	Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain (GlobeNewswire)
Mar-19-26 03:00PM	Pelthos Therapeutics Inc (PTHS) Q4 2025 Earnings Call Highlights: Prescription Surge and ... (GuruFocus.com)
06:30AM	Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-12-26 08:30AM	Pelthos Therapeutics to Present at 38th Annual ROTH Conference (GlobeNewswire)
Mar-09-26 08:30AM	Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 (GlobeNewswire)
Feb-23-26 08:00AM	Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire) +5.04%
Jan-13-26 08:30AM	Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance (GlobeNewswire)
Jan-05-26 07:30AM	Pelthos Therapeutics Acquires Xeglyze (abametapir) Topical Treatment for Head Lice (GlobeNewswire) -9.03%
05:57PM	Loading…
Dec-23-25 05:57PM	Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn (GlobeNewswire)
Dec-04-25 07:00AM	Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI (berdazimer) Topical Gel, 10.3% (GlobeNewswire)
Dec-02-25 08:00AM	Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 06:45AM	Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results (GlobeNewswire) -7.27%
Nov-07-25 08:00AM	Pelthos Therapeutics Acquires Xepi (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing (GlobeNewswire) -8.07%
Nov-05-25 08:00AM	Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025 (GlobeNewswire) +6.47%
Oct-09-25 08:00AM	Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum (GlobeNewswire) -7.89%
Sep-08-25 08:30AM	Pelthos Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire) +13.96%
Sep-02-25 08:00AM	Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference (GlobeNewswire) -5.03%
Aug-18-25 08:00AM	Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update (GlobeNewswire)
Jul-10-25 08:00AM	Pelthos Therapeutics Launches ZELSUVMI (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum (GlobeNewswire) +60.78%
Jul-02-25 07:00AM	Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement (GlobeNewswire) +22.22%
07:00AM	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (GlobeNewswire)

Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. It produces products under its proprietary nitic oxide-based technology platform Nitricil. Its main product is a topical gel for the treatment of molluscum contagiosum. The company was founded on March 19, 2021 and is headquartered in Durham, NC.

CEOMr. Scott M. Plesha

Chief Commercial OfficerMr. Sai Rangarao M.B.A.

CFOMr. John M. Gay CPA

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Friedberg Ezra M	Director	Jun 15 '26	Sale	27.29	283	7,724	81,600	Jun 17 05:25 PM
Davis Todd C	Director	Jun 11 '26	Buy	27.82	35,948	999,983	75,834	Jun 15 05:25 PM
Francis Knuettel II	CFO, Treas & Secty	May 22 '26	Sale	26.84	1,500	40,265	11,316	May 26 07:17 PM
Francis Knuettel II	Officer	May 22 '26	Proposed Sale	27.11	1,720	46,629		May 22 12:46 PM
Malamut Richard	Director	Apr 02 '26	Sale	20.92	590	12,340	27,422	Apr 06 05:03 PM
Friedberg Ezra M	Director	Apr 02 '26	Sale	20.92	558	11,671	82,027	Apr 06 05:03 PM
Pauls Matthew	Director	Apr 02 '26	Sale	20.92	786	16,439	15,150	Apr 06 05:02 PM
Greenleaf Peter	Director	Apr 02 '26	Sale	20.92	797	16,670	24,681	Apr 06 05:01 PM
Pauls Matthew	Director	Oct 02 '25	Option Exercise	0.00	2,123	0	10,616	Dec 12 05:01 PM
Pauls Matthew	Director	Jul 02 '25	Option Exercise	0.00	8,493	0	8,493	Dec 12 05:01 PM
Friedberg Ezra M	Director	Nov 25 '25	Sale	28.03	10,000	280,280	30,000	Nov 26 12:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTHS

Pelthos Therapeutics Inc

Upgrade your Finviz experience